Safety and Efficacy of a Lentiviral Vector Containing Three Anti-HIV Genes—CCR5 Ribozyme, Tat-rev siRNA, and TAR Decoy—in SCID-hu Mouse–Derived T Cells

This publication has 48 references indexed in Scilit:

• Ex Vivo Selection and Expansion of Cells Based on Expression of a Mutated Inosine Monophosphate Dehydrogenase 2 after HIV Vector Transduction: Effects on Lymphocytes, Monocytes, and CD34+ Stem Cells
  Molecular Therapy, 2006
• T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery
  Gene Therapy, 2006
• Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome
  Human Gene Therapy, 2006
• Off-target effects by siRNA can induce toxic phenotype
  RNA, 2006
• Long-Term Inhibition of HIV-1 Infection in Primary Hematopoietic Cells by Lentiviral Vector Delivery of a Triple Combination of Anti-HIV shRNA, Anti-CCR5 Ribozyme, and a Nucleolar-Localizing TAR Decoy
  Molecular Therapy, 2005
• Current status of gene therapy strategies to treat HIV/AIDS
  Molecular Therapy, 2005
• Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load
  Molecular Therapy, 2004
• Downregulation of the CCR5 β-Chemokine Receptor and Inhibition of HIV-1 Infection by Stable VA1-Ribozyme Chimeric Transcripts
  Antisense and Nucleic Acid Drug Development, 2000
• CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and Disease
  Annual Review of Immunology, 1999
• In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
  Science, 1996